Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

CAPS Rating: 2 out of 5

The Company is engaged in the discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules.

Recs

0
Player Avatar IBDContrarian (21.17) Submitted: 6/27/2012 1:54:03 PM : Underperform Start Price: $17.55 ARIA Score: +18.43

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yieldMEDICAL 5 95 DB NEG EARNINGS

Report this Post 2 Replies
Member Avatar IBDContrarian (21.17) Submitted: 3/2/2013 3:46:04 PM
Recs: 0

24 59 DB- no earnings. Still hate it, keep selling.

Report this Post
Member Avatar IBDContrarian (21.17) Submitted: 4/6/2013 1:46:57 PM
Recs: 0

24 15 DE, parity, close.

Report this Post

Featured Broker Partners


Advertisement